Results 101 to 110 of about 50,409 (184)
Novel mechanisms of resistance to vemurafenib in melanoma – V600E B-Raf reversion and switching VEGF-A splice isoform expression [PDF]
, 2014 Targeting activating mutations in the proto-oncogene B-Raf, in melanoma, has led to increases in progression free survival. Treatment with vemurafenib, which inhibits the most common activating-mutated form of B-Raf (B-RafV600E), eventually results in ...
Bates, DO +4 more
core +1 more source
British Journal of Pharmacology, Volume 183, Issue 10, Page 2177-2196, May 2026.Addressing complexity in the study of life sciences through Systems Biology and Systems Medicine has been transformative, making Systems Pharmacology the next logical step. In this review, we focus on physical stimuli, whose potential in pharmacology has been neglected, despite demonstrated therapeutic properties.
Veronica Paparozzi +10 more
wiley +1 more source
Opioids in breast cancer: Between analgesia and modulation of tumour progression
British Journal of Pharmacology, Volume 183, Issue 9, Page 1727-1746, May 2026.Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun +2 more
wiley +1 more source
Revista do Colégio Brasileiro de Cirurgiões, 2013 OBJETIVO: Avaliar a frequência da mutação V600E do gene BRAF em pacientes com mais de 65 anos de idade submetidos à tireoidectomia, correlacionando sua presença ou ausência com as diferentes lesões histológicas, com as variantes e com fatores ...
Antonio Augusto T. Bertelli +5 more
doaj
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review
British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos +16 more
wiley +1 more source
Glucose Metabolism Regulating Colorectal Cancer Initiation and Progression
Cancer Science, Volume 117, Issue 5, Page 1199-1208, May 2026.Drugs and compounds targeting glycolysis in CRC and the mechanisms by which these drugs inhibit their respective targets. ABSTRACT Colorectal cancer (CRC) is one of the most common types of invasive cancer worldwide, which has the characteristics of poor curative effect and poor prognosis. Increasing evidence suggests that hyperactivated glucose uptake
Meiyi Lin, Junpeng Cui
wiley +1 more source
Defining the clinical role of the mammalian target of rapamycin (mTOR) in lung cancer
, 2010 Lung cancer is the biggest cancer killer. Most patients present with advanced disease. These diseases are not amenable to surgery which currently provides the best chance of cure.
Dhillon, Perminder Tony Singh +1 more
core +1 more source
Cancer Science, Volume 117, Issue 5, Page 1235-1243, May 2026.RUNX‐dependent transcriptional control of SOS1 reinforces HER2–RAS signaling and may attenuate responses to HER2‐targeted therapies in HER2‐positive gastric cancer. ABSTRACT HER2‐positive gastric cancer represents a distinct molecular subtype characterized by chromosomal instability, variable HER2 amplification, and substantial intratumoral ...
Tatsuya Masuda +3 more
wiley +1 more source
Pattern of expression of the jun family of transcription factors during the early development of the inner ear: implications in apoptosis [PDF]
, 1999 8 pages, 6 figures, 1 table.Jun transcription factors have been implicated in the regulation of cell proliferation, differentiation and apoptosis. We have investigated the relationship between Jun expression and cell death in the developing chicken inner
Cañón, Susana +5 more
core
Genome-wide analysis to predict protein sequence variations that change phosphorylation sites or their corresponding kinases [PDF]
, 2008 We define phosphovariants as genetic variations that change phosphorylation sites or their interacting kinases. Considering the essential role of phosphorylation in protein functions, it is highly likely that phosphovariants change protein functions and ...
Gil-Mi Ryu +4 more
core +1 more source